Background
==========

Pharmacokinetics (PK) is a very important translational research field, which studies drug absorption, disposition, metabolism, excretion, and transportation (ADMET). PK systematically investigates the physiological and biochemical mechanisms of drug exposure in multiple tissue types, cells, animals, and human subjects \[[@B1]\]. There are two major molecular mechanisms of a drug's PK: metabolism and transportation. The drug metabolism mainly happens in the gut and liver; while drug transportation exists in all tissue types. If the PK can be interpreted as how a body does on the drug, pharmacodynamics (PD) can be defined as how a drug does on the body. A drug's pharmacodynamics effect ranges widely from the molecular signals (such as its targets or downstream biomarkers) to clinical symptoms (such as the efficacy or side effect endpoints) \[[@B1]\].

Drug-drug interaction (DDI) is another important pharmacology concept. It is defined as whether one drug's PK or PD response is changed due to the presence of another drug. PD based drug interaction has a wide range of interpretations (i.e. from molecular markers to clinical endpoints). PK based drug interaction mechanism is very well defined: metabolism enzyme based and transporter based DDIs. Pharmacogenetic (PG) variations in a drug's PK and PD pathways can also affect its responses \[[@B1]\]. In this paper, we will focus our discussion on the PK, PK based DDI, and PK related PG.

Although significant efforts have been invested to integrate biochemistry, genetics, and clinical information for drugs, significant gaps exist in the area of PK. For example DrugBank (<http://www.drugbank.ca/>) doesn't have *in vitro* PK and its associated DDI data; DiDB (<http://www.druginteractioninfo.org/>) doesn't have sufficient PG data; and PharmGKB (<http://www.pharmgkb.org/>) doesn't have sufficient *in vivo* and *in vitro* PK and its associated DDI data. As an alternative approach to collect PK from the published literature, text mining has just started to be explored \[[@B1]-[@B4]\].

From either database construction or literature mining, the main challenge of PK data integration is the lack of PK ontology. This paper developed a PK ontology first. Then, a PK corpus was constructed. It facilitated DDI text mining from the literature.

Construction and content
========================

PK Ontology is composed of several components: experiments, metabolism, transporter, drug, and subject (Table [1](#T1){ref-type="table"}). Our primary contribution is the ontology development for the PK experiment, and integration of the PK experiment ontology with other PK-related ontologies.

###### 

PK ontology categories

  **Categories**                 **Description**                                                                                                            **Resources**
  ------------------------------ -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  Pharmacokinetics Experiments   Pharmacokinetics studies and parameters. There are two major categories: *in vitro* experiments and *in vivo* studies.     Manually accumulated from text books and literatures.
  Transporters                   Drug transportation enzymes                                                                                                <http://www.tcdb.org>
  Metabolism Enzymes             Drug metabolism enzymes                                                                                                    <http://www.cypalleles.ki.se/>
  Drugs                          Drug names                                                                                                                 <http://www.drugbank.ca/>
  Subjects                       Subject description for a pharmacokinetics study. It is composed three categories: disease, physiology, and demographics   <http://bioportal.bioontology.org/ontologies/42056>
                                                                                                                                                            <http://bioportal.bioontology.org/ontologies/39343>
                                                                                                                                                            <http://bioportal.bioontology.org/ontologies/42067>

*Experiment* specifies *in vitro* and *in vivo* PK studies and their associated PK parameters. Table [2](#T2){ref-type="table"} presents definitions and units of the *in vitro* PK parameters. The PK parameters of the single drug metabolism experiment include Michaelis-Menten constant (K~m~), maximum velocity of the enzyme activity (V~max~), intrinsic clearance (CL~int~), metabolic ratio, and fraction of metabolism by an enzyme (fm~enzyme~) \[[@B5]\]. In the transporter experiment, the PK parameters include apparent permeability (Papp), ratio of the basolateral to apical permeability and apical to basolateral permeability (Re), radioactivity, and uptake volume \[[@B6]\]. There are multiple drug interaction mechanisms: competitive inhibition, non-competitive inhibition, uncompetitive inhibition, mechanism based inhibition, and induction \[[@B7]\]. IC~50~ is the inhibition concentration that inhibits to 50% enzyme activity; it is substrate dependent; and it doesn't imply the inhibition mechanism. K~i~ is the inhibition rate constant for competitive inhibition, noncompetitive inhibition, and uncompetitive inhibition. It represents the inhibition concentration that inhibits to 50% enzyme activity, and it is substrate concentration independent. K~deg~ is the degradation rate constant for the enzyme. K~I~ is the concentration of inhibitor associated with half maximal Inactivation in the mechanism based inhibition; and K~inact~ is the maximum degradation rate constant in the presence of a high concentration of inhibitor in the mechanism based inhibition. E~max~ is the maximum induction rate, and EC~50~ is the concentration of inducer that is associated with the half maximal induction

###### 

***In vitro*PK parameters**

  **Experiment types**                 **Parameters**                                                                                                            **Description**                                                                                                                 **Unit**                  **References**
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ------------------------- -----------------------------
  Single Drug Metabolism Experiment    K~m~                                                                                                                      Michaelis-Menten constant.                                                                                                      mg L^-1^                  Segel p28.
                                       V~max~                                                                                                                    Maximum velocity of the enzyme activity.                                                                                        mg h^-1^ mg^-1^ protein   Segel p19
                                       CL~int~                                                                                                                   Intrinsic metabolic clearance is defined as ratio of maximum metabolism rate, Vmax, and the Michaelis-Menten constant, Km.      ml h^-1^ mg^-1^ protein   RT p165
                                       Metabolic ratio                                                                                                           Parent drug/metabolite concentration ratio                                                                                      NA                         
                                       fm~enzyme~                                                                                                                Fraction of drug systemically available that is converted to a metabolite through a specific enzyme.                            NA                        RT xiii
  Single Drug Transporter Experiment   Papp                                                                                                                      The apparent permeability of compounds across the monolayer cells.                                                              cm/sec                    Transport Consortium
                                       Re                                                                                                                        Re is the ratio of basolateral to apical over apical to basolateral.                                                            NA                        Transport Consortium
                                       Radioactivity                                                                                                             Total radioactivity in plasma and bile samples is measured in a liquid scintillation counter                                    dpm/mg protein            Transport Consortium
                                       Uptake Volume                                                                                                             The amount of radioactivity associated with the cells divided by its concentration in the incubation medium.                    ul/mg protein             Transport Consortium
  Drug Interaction Experiment          IC~50~                                                                                                                    Inhibitor concentration that inhibits to 50% of enzyme activity.                                                                mg L^-1^                   
                                       K~i~                                                                                                                      Inhibition rate constant for competitive inhibition, noncompetitive inhibition, and uncompetitive inhibition.                   mg L^-1^                  Segel p103
                                       K~deg~                                                                                                                    The natural degradation rate constant for the Enzyme.                                                                           h^-1^                     Rostami-Hodjegan and Tucker
                                       K~I~                                                                                                                      The concentration of inhibitor associated with half maximal Inactivation in the mechanism based inhibition.                     mg L^-1^                  Rostami-Hodjegan and Tucker
                                       K~inact~                                                                                                                  The maximum degradation rate constant in the presence of a high concentration of inhibitor in the mechanism based inhibition.   h^-1^                     Rostami-Hodjegan and Tucker
                                       E~max~                                                                                                                    Maximum induction rate                                                                                                          Unit free                 Rostami-Hodjegan and Tucker
                                       EC~50~                                                                                                                    The concentration of inducer that is associated with the half maximal induction.                                                mg L^-1^                  Rostami-Hodjegan and Tucker
  Type of Drug Interactions            Competitive inhibition, noncompetitive inhibition, uncompetitive inhibition, mechanism based inhibition, and induction.   Rostami-Hodjegan and Tucker                                                                                                                                

Note: Segel H. Irwin. Enzyme Kinetics -- Behavior and analysis of rapid equilibrium and steady state enzyme systems. John Wiley & Sons, Inc. 1975, New York. Rostami-Hodjegan Amin and Tucker Geoff 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discovery Today, 2004, 1, 441--448. The International Transporter Consortium, Membrane transporters in drug development. Nature Review Drug Discovery, 9, 215--236. Rowland Malcolm and Tozer N. Thomas Clinical Pharmacokinetics Concepts and Applications, 3^rd^ edition. 1995, Lippincott Williams & Wilkins.

The *in vitro* experiment conditions are presented in Table [3](#T3){ref-type="table"}. Metabolism enzyme experiment conditions include buffer, NADPH sources, and protein sources. In particular, protein sources include recombinant enzymes, microsomes, hepatocytes, and etc. Sometimes, genotype information is available for the microsome or hepatocyte samples. Transporter experiment conditions include bi-directional transporter, uptake/efflux, and ATPase. Other factors of *in vitro* experiments include pre-incubation time, incubation time, quantification methods, sample size, and data analysis methods. All these info can be found in the FDA website (<http://www.abclabs.com/Portals/0/FDAGuidance_DraftDrugInteractionStudies2006.pdf>).

###### 

***In vitro*experiment conditions**

  ----------------------------------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  ***Experimental Conditions:***                        **Drugs**                                                                             **Substrate, metabolite, and inhibitor/inducer**                                                                        **FDA Drug Interaction Guidance, 2006**
  Metabolism Enzymes                                    Buffer                                                                                Salt composition                                                                                                         
  EDTA concentration                                                                                                                                                                                                                                                  
  MgCl~2~ concentration Cytochrome b~5~ concentration                                                                                                                                                                                                                 
  NADPH source                                          Concentration of exogenous NADPH added isocytrate dehydrogenase + NADP                                                                                                                                        
  protein                                               Non-recombinant enzymes                                                               Microsomes (human liver microsomes, human intestine microsomes, S9 fraction, cytosol, whole cell lysate, hepatocytes)    
  Recombinant enzymes                                   Enzyme name                                                                           mg/mL or uM                                                                                                              
  genotype                                                                                                                                                                                                                                                            
  Transporters                                          Bi-Directional                                                                        CHO; Caco-2 cells; HEK-293; Hepa-RG; LLC; LLC-PK1 MDR1 cells; MDCK; MDCK-MDR1 cells; Suspension Hepatocyte               
  Transport                                                                                                                                                                                                                                                           
  Uptake/efflux                                         tumor cells, cDNA transfected cells, oocytes injected with cRNA of transporters                                                                                                                               
  ATPase                                                membrane vesicles from various tissues or cells expressing P-gp, Reconstituted P-gp                                                                                                                           
  Other factors                                         Pre-incubation time                                                                                                                                                                                           
  Incubation time                                                                                                                                                                                                                                                     
  Quantification methods                                HPLC/UV, LC/MS/MS, LC/MS, radiographic                                                                                                                                                                        
  Sample size                                                                                                                                                                                                                                                         
                                                        Data Analysis                                                                         log-linear regression, plotting; and nonlinear regression                                                                
  ----------------------------------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -----------------------------------------

The *in vivo* PK parameters are presented in Table [4](#T4){ref-type="table"}. All of the information are summarized from two text books \[[@B1],[@B8]\]. There are several main classes of PK parameters. Area under the concentration curve parameters are (AUC~inf~, AUC~SS~, AUC~t~, AUMC); drug clearance parameters are (CL, CL~b~, CL~u~, CL~H~, CL~R~, CL~po~, CL~IV~, CL~int~, CL~12~); drug concentration parameters are (C~max~, C~SS~); extraction ratio and bioavailability parameters are (E, E~H~, F, F~G~, F~H~, F~R~, f~e~, f~m~); rate constants include elimination rate constant k, absorption rate constant ka, urinary excretion rate constant ke, Michaelis-Menten constant Km, distribution rate constants (k~12~, k~21~), and two rate constants in the two-compartment model (λ~1~, λ~2~); blood flow rate (Q, Q~H~); time parameters (t~max~, t~1/2~); volume distribution parameters (V, V~b~, V~1~, V~2~, V~ss~); maximum rate of metabolism, Vmax; and ratios of PK parameters that present the extend of the drug interaction, (AUCR, CL ratio, Cmax ratio, C~ss~ ratio, t~1/2~ ratio).

###### 

***In vivo*PK studies**

  **Category**              **Name**                                                                                                                                                                                                                                                                                                                                               **Description**                                                                                                              **Unit**     **reference**
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------- ------------ ---------------
  PK parameters             AUC~inf~                                                                                                                                                                                                                                                                                                                                               Area under the drug concentration time curve.                                                                                mg h L^-1^   RT p37
  AUC~SS~                   Area under the drug concentration time curve within a dosing curve at steady state.                                                                                                                                                                                                                                                                    mg h L^-1^                                                                                                                   RT pxi       
  AUC~t~                    Area under the drug concentration time curve from time 0 to t.                                                                                                                                                                                                                                                                                         mg h L^-1^                                                                                                                   RT p37       
  AUMC                      Area under the first moment of concentration versus time curve.                                                                                                                                                                                                                                                                                        mg^2^ h L^-2^                                                                                                                RT p486      
  AUCR                      AUC ratio (drug interaction parameter).                                                                                                                                                                                                                                                                                                                Unit free                                                                                                                                 
  CL                        Total clearance is defined as the proportionality factor relating rate of drug elimination to the plasma drug concentration.                                                                                                                                                                                                                           ml h^-1^                                                                                                                     RT p23       
  CL~b~                     Blood clearance is defined as the proportionality factor relating rate of drug elimination to the blood drug concentration.                                                                                                                                                                                                                            ml h^-1^                                                                                                                     RT p160      
  CL~u~                     Unbound clearance is defined as the proportionality factor relating rate of drug elimination to the unbounded plasma drug concentration.                                                                                                                                                                                                               ml h^-1^                                                                                                                     RT p163      
  CL~H~                     Hepatic portion of the total clearance.                                                                                                                                                                                                                                                                                                                ml h^-1^                                                                                                                     RT p161      
  CL~R~                     Renal portion of the total clearance.                                                                                                                                                                                                                                                                                                                  ml h^-1^                                                                                                                     RT p161      
  CL~po~                    Total clearance of drug following an oral dose.                                                                                                                                                                                                                                                                                                        ml h^-1^                                                                                                                                  
  CL~IV~                    Total clearance of drug following an IV dose.                                                                                                                                                                                                                                                                                                          ml h^-1^                                                                                                                                  
  CL~int~                   Intrinsic metabolic clearance is defined as ratio of maximum metabolism rate, Vmax, and the Michaelis-Menten constant, Km.                                                                                                                                                                                                                             ml h^-1^                                                                                                                     RT p165      
  CL~12~                    Inter-compartment distribution between the central compartment and the peripheral compartment.                                                                                                                                                                                                                                                         ml h^-1^                                                                                                                                  
  CL ratio                  Ratio of the clearance (drug interaction parameter).                                                                                                                                                                                                                                                                                                   Unit free                                                                                                                                 
  C~max~                    Highest drug concentration observed in plasma following administration of an extravascular dose.                                                                                                                                                                                                                                                       mg L^-1^                                                                                                                     RT pxii      
  C~max~ ratio              The ratio of C~max~ (drug interaction parameter).                                                                                                                                                                                                                                                                                                      Unit free                                                                                                                                 
  C~ss~                     Concentration of drug in plasma at steady state during a constant rate intravenous infusion.                                                                                                                                                                                                                                                           mg L^-1^                                                                                                                     RT pxii      
  C~ss~ ratio               The ratio of C~ss~ (drug interaction parameter).                                                                                                                                                                                                                                                                                                       Unit free                                                                                                                                 
  E                         Extraction ratio is defined as the ratio between blood clearance, CL~b~, and the blood flow.                                                                                                                                                                                                                                                           Unit free                                                                                                                    RT p159      
  E~H~                      Hepatic extraction ratio.                                                                                                                                                                                                                                                                                                                              Unit free                                                                                                                    RT p161      
  F                         Bioavailability is defined as the proportion of the drug reaches the systemic blood.                                                                                                                                                                                                                                                                   Unit free                                                                                                                    RT p42       
  F~G~                      Gut-wall bioavailability.                                                                                                                                                                                                                                                                                                                              Unit free                                                                                                                                 
  F~H~                      Hepatic bioavailability.                                                                                                                                                                                                                                                                                                                               Unit free                                                                                                                    RT p167      
  F~R~                      Renal bioavailability.                                                                                                                                                                                                                                                                                                                                 Unit free                                                                                                                    RT p170      
  fe                        Fraction of drug systemically available that is excreted unchanged in urine.                                                                                                                                                                                                                                                                           Unit free                                                                                                                    RT pxiii     
  fm                        Fraction of drug systemically available that is converted to a metabolite.                                                                                                                                                                                                                                                                             Unit free                                                                                                                    RT pxiii     
  fu                        Ratio of unbound and total drug concentrations in plasma.                                                                                                                                                                                                                                                                                              Unit free                                                                                                                    RT pxiii     
  k                         Elimination rate constant.                                                                                                                                                                                                                                                                                                                             h^-1^                                                                                                                        RT pxiii     
  K~12~, k~21~              Distribution rate constants between central compartment and peripheral compartment.                                                                                                                                                                                                                                                                    h^-1^                                                                                                                                     
  ka                        Absorption rate constant.                                                                                                                                                                                                                                                                                                                              h^-1^                                                                                                                        RT pxiii     
  ke                        Urinary excretion rate constant.                                                                                                                                                                                                                                                                                                                       h^-1^                                                                                                                        RT pxiii     
  km                        Rate constant for the elimination of a metabolite.                                                                                                                                                                                                                                                                                                     h^-1^                                                                                                                        RT pxiii     
  Km                        Michaelis-Menten constant.                                                                                                                                                                                                                                                                                                                             mg L^-1^                                                                                                                     RT pxiii     
  MRT                       Mean time a molecular resides in body.                                                                                                                                                                                                                                                                                                                 h                                                                                                                            RT pxiv      
  Q                         Blood flow.                                                                                                                                                                                                                                                                                                                                            L h^-1^                                                                                                                      RT pxiv      
  Q~H~                      Hepatic blood flow.                                                                                                                                                                                                                                                                                                                                    L h^-1^                                                                                                                      RT pxiv      
  t~max~                    Time at which the highest drug concentration occurs following administration of an extravascular dose.                                                                                                                                                                                                                                                 h                                                                                                                            RT pxiv      
  t~1/2~                    Half-life of the drug disposition.                                                                                                                                                                                                                                                                                                                     h                                                                                                                            RT pxiv      
  t~1/2~ ratio              Half-life ratio (drug interaction parameter).                                                                                                                                                                                                                                                                                                          Unit free                                                                                                                                 
  t~1/2,α~                  Half-life of the fast phase drug disposition.                                                                                                                                                                                                                                                                                                          h                                                                                                                                         
  t~1/2,β~                  Half-life of the slow phase drug disposition.                                                                                                                                                                                                                                                                                                          h                                                                                                                                         
  V                         Volume of distribution based on drug concentration in plasma.                                                                                                                                                                                                                                                                                          L                                                                                                                            RT pxiv      
  V~b~                      Volume of distribution based on drug concentration in blood.                                                                                                                                                                                                                                                                                           L                                                                                                                            RT pxiv      
  V~1~                      Volume of distribution of the central compartment.                                                                                                                                                                                                                                                                                                     L                                                                                                                            RT pxiv      
  V~2~                      Volume of distribution of the peripheral compartment.                                                                                                                                                                                                                                                                                                  L                                                                                                                                         
  V~ss~                     Volume of distribution under the steady state concentration.                                                                                                                                                                                                                                                                                           L                                                                                                                            RT pxiv      
  Vmax                      Maximum rate of metabolism by an enzymatically mediated reaction.                                                                                                                                                                                                                                                                                      mg h^-1^                                                                                                                     RT pxiv      
  λ~1~, λ~2~                Disposition rate constants in a two-compartment model.                                                                                                                                                                                                                                                                                                 h^-1^                                                                                                                        GP p84       
  Pharmacokinetics Models   Non-Compartment                                                                                                                                                                                                                                                                                                                                        Use drug concentration measurements directly to estimate PK parameters, such as AUC, CL, C~max~, T~max~, t~1/2~, F, and V.   GP p409      
  One Compartment Model     It assumes the whole body is a homogeneous compartment, and the distribution of the drug from the blood to tissue is very fast. It assumes either a first order or a zero order absorption rate and a first order eliminate rate. Its PK parameters include (ka, V, CL, F).                                                                            RT p34                                                                                                                                    
  GP p1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Two Compartment Model     It assumes the whole body can be divided into two compartments: central compartment (i.e. systemic compartment) and peripheral compartment (i.e. tissue compartment). It assumes either a first order or a zero order absorption rate and a first order eliminate and distribution rates. Its PK parameters include (ka, V~1~, V~2~, CL, CL~12~, F).   GP p84                                                                                                                                    
  Study Designs             Hypothesis                                                                                                                                                                                                                                                                                                                                             Bioequivalence, drug interaction, pharmacogenetics, and disease conditions.                                                               
  Design                    Single arm or multiple arms; cross-over or fixed order design; with or without randomization; with or without stratification; prescreening or no-prescreening; prospective or retrospective studies; and case reports or cohort studies.                                                                                                                                                                                                                                                         
  Sample size               The number of subjects, and the number of plasma or urine samples per subject.                                                                                                                                                                                                                                                                                                                                                                                                                   
  Time points               Sampling time points and dosing time points.                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Sample types              Blood, plasma, and urine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Dose                      Subject specific doses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Quantification methods    HPLC/UV, LC/MS/MS, LC/MS, radiographic                                                                                                                                                                                                                                                                                                                                                                                                                                                           

Rowland Malcolm and Tozer N. Thomas Clinical Pharmacokinetics Concepts and Applications, 3^rd^ edition. 1995, Lippincott Williams & Wilkins.

Gibaldi Milo and Perrier Donald. Pharmacokinetics, 2^nd^ edition. 1982, Dekker.

It is also shown in Table [4](#T4){ref-type="table"} that two types of pharmacokinetics models are usually presented in the literature: non-compartment model and one or two-compartment models. There are multiple items need to be considered in an *in vivo* PK study. The hypotheses include the effect of bioequivalence, drug interaction, pharmacogenetics, and disease conditions on a drug's PK. The design strategies are very diverse: single arm or multiple arms, cross-over or fixed order design, with or without randomization, with or without stratification, pre-screening or no-pre-screening based on genetic information, prospective or retrospective studies, and case reports or cohort studies. The sample size includes the number of subjects, and the number of plasma or urine samples per subject. The time points include sampling time points and dosing time points. The sample type includes blood, plasma, and urine. The drug quantification methods include HPLC/UV, LC/MS/MS, LC/MS, and radiographic.

CYP450 family enzymes predominantly exist in the gut wall and liver. Transporters are tissue specific. Table [5](#T5){ref-type="table"} presents the tissue specific transports and their functions. Probe drug is another important concept in the pharmacology research. An enzyme's probe substrate means that this substrate is primarily metabolized or transported by this enzyme. In order to experimentally prove whether a new drug inhibits or induces an enzyme, its probe substrate is always utilized to demonstrate this enzyme's activity before and after inhibition or induction. An enzyme's probe inhibitor or inducer means that it inhibits or induces this enzyme primarily. Similarly, an enzyme's probe inhibitor needs to be utilized if we investigate whether a drug is metabolized by this enzyme. Table [6](#T6){ref-type="table"} presents all the probe inhibitors, inducers, and substrates of CYP enzymes. Table [7](#T7){ref-type="table"} presents all the probe inhibitors, inducers, and substrates of the transporters. All these information were collected from industry standard (<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm>), reviewed in the top pharmacology journal \[[@B9]\].

###### 

Tissue specific transporters

  **Gene**    **Aliases**                     **Tissue type**                                                                                                                              **Function**
  ----------- ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- --------------
  *ABCB1*     P-gp, MDR1                      Intestinal enterocyte, kidney proximal tubule, hepatocyte (canalicular), brain endothelia                                                    Efflux
  *ABCG2*     BCRP                            Intestinal enterocyte, hepatocyte (canalicular), kidney proximal tubule, brain endothelia, placenta, stem cells, mammary gland (lactating)   Efflux
  *SLCO1B1*   OATP1B1, OATP-C, OATP2, LST-1   Hepatocyte (sinusoidal)                                                                                                                      Uptake
  *SLCO1B3*   OATP1B3, OATP-8                 Hepatocyte (sinusoidal)                                                                                                                      Uptake
  *SLC22A2*   OCT2                            Kidney proximal tubule                                                                                                                       Uptake
  *SLC22A6*   OAT1                            Kidney proximal tubule, placenta                                                                                                             Uptake
  *SLC22A8*   OAT3                            Kidney proximal tubule, choroid plexus, brain endothelia                                                                                     Uptake

###### 

***In vivo*probe inhibitors/inducers/substrates of CYP enzymes**

  **CYP enzymes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Inhibitors**                                                                                                                                                                                                                                                                                                         **Inducers**                                                                                                                                                                                                                       **Substrates**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CYP1A2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Ciprofloxacin, enoxacin, fluvoxamine, Methoxsalen, mexiletine, oral contraceptives, phenylpropanolamine, thiabendazole, vemurafenib, zileuton, acyclovir, allopurinol, caffeine, cimetidine, daidzein, disulfiram, Echinacea, famotidine, norfloxacin, propafenone, propranolol, terbinafine, ticlopidine, verapamil   Montelukast, phenytoin, smokers versus non-smokers, moricizine, omeprazole, phenobarbital                                                                                                                                          Alosetron, caffeine, duloxetine, melatonin, ramelteon, tacrine, tizanidine, theophylline, tizanidine
  CYP2B6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Clopidogrel, ticlopidine prasugrel                                                                                                                                                                                                                                                                                     Efavirenz, rifampin, nevirapine                                                                                                                                                                                                    Bupropion, efavirenz
  CYP2C8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Gemfibrozil, fluvoxamine, ketoconazole, trimethoprim                                                                                                                                                                                                                                                                   Rifampin                                                                                                                                                                                                                           Repaglinide, Paclitaxel
  CYP2C9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Amiodarone, fluconazole, miconazole, oxandrolone, capecitabine, cotrimoxazole, etravirine, fluvastatin, fluvoxamine, metronidazole, sulfinpyrazone, tigecycline, voriconazole, zafirlukast                                                                                                                             Carbamazepine, rifampin, aprepitant, bosentan, phenobarbital, St. John's wort                                                                                                                                                      Celecoxib, Warfarin, phenytoin
  CYP2C19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Fluconazole, fluvoxamine, ticlopidine, esomeprazole, fluoxetine, moclobemide, omeprazole, voriconazole, allicin (garlic derivative), armodafinil, carbamazepine, cimetidine, etravirine, human growth hormone (rhGH), felbamate, ketoconazole, oral contraceptives                                                     Rifampin, artemisinin                                                                                                                                                                                                              Clobazam, lansoprazole, omeprazole, Smephenytoin, S-mephenytoin
  CYP3A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole,                                                                                                                                                                                                                                     Avasimibe, carbamazepine, phenytoin, rifampin, St. John's wort, bosentan, efavirenz, etravirine, modafinil, nafcillin, amprenavir, aprepitant, armodafinil, clobazamechinacea, pioglitazone, prednisone, rufinamide, vemurafenib   Alfentanil, aprepitant, budesonide, buspirone, conivaptan, darifenacin, darunavir, dasatinib, dronedarone, eletriptan, eplerenone, everolimus, felodipine, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, quetiapine, saquinavir, sildenafil, simvastatin, sirolimus, tolvaptan, tipranavir, triazolam, ticagrelor, vardenafil, Alfentanil, astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine
  ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole, amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil, alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  CYP2D6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Bupropion, fluoxetine, paroxetine, quinidine, cinacalcet, duloxetine, terbinafine,                                                                                                                                                                                                                                     NA                                                                                                                                                                                                                                 Atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, Thioridazine, pimozide
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                amiodarone, celecoxib, clobazam, cimetidine, desvenlafaxine, diltiazem, diphenhydramine, echinacea, escitalopram, febuxostat, gefitinib, hydralazine, hydroxychloroquine, imatinib, methadone, oral contraceptives, pazopanib, propafenone, ranitidine, ritonavir, sertraline, telithromycin, verapamil, vemurafenib                                                                                                                                                                                                                                       

###### 

***In vivo*probe inhibitors/inducers/substrates of selected transporters**

  **Transporter**   **Inhibitor**                                                                                                                                                                                                                                               **Inducer**                                                                           **Substrate**
  ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  P-gp              Amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, dronedarone, erythromycin, felodipine, itraconazole, ketoconazole, lopinavir and ritonavir, quercetin, quinidine, ranolazine, ticagrelor, verapamil   Avasimibe, carbamazepine, phenytoin, rifampin, St John's wort, tipranavir/ritonavir   Aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan
  BCRP              Cyclosporine, elacridar (GF120918), eltrombopag, gefitinib                                                                                                                                                                                                  NA                                                                                    Methotrexate, mitoxantrone, imatinib, irrinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan
  OATP1B1           Atazanavir, cyclosporine, eltrombopag, gemfibrozil, lopinavir, rifampin, ritonavir, saquinavir, tipranavir                                                                                                                                                  NA                                                                                    Atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 (active metabolite of irinotecan), rosuvastatin, simvastatin acid, pitavastatin, pravastatin, repaglinide, rifampin, valsartan, olmesartan
  OATP1B3           Atazanavir, cyclosporine, lopinavir, rifampin, ritonavir, saquinavir                                                                                                                                                                                        NA                                                                                    Atorvastatin, rosuvastatin, pitavastatin, telmisartan, valsartan, olmesartan
  OCT2              Cimetidine, quinidine                                                                                                                                                                                                                                       NA                                                                                    Amantadine, amiloride, cimetidine, dopamine, famotidine, memantine, metformin, pindolol, procainamide, ranitidine, varenicline, oxaliplatin
  OAT1              Probenecid                                                                                                                                                                                                                                                  NA                                                                                    Adefovir, captopril, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, zalcitabine, zidovudine
  OAT3              Probenecid cimetidine, diclofenac                                                                                                                                                                                                                           NA                                                                                    Acyclovir, bumetanide, ciprofloxacin, famotidine, furosemide, methotrexate, zidovudine, oseltamivir acid, (the active metabolite of oseltamivir), penicillin G, pravastatin, rosuvastatin, sitagliptin

*Metabolism* The cytochrome P450 superfamily (officially abbreviated as CYP) is a large and diverse group of enzymes that catalyze the oxidation of organic substances. The substrates of CYP enzymes include metabolic intermediates such as lipids and steroidal hormones, as well as xenobiotic substances such as drugs and other toxic chemicals. CYPs are the major enzymes involved in drug metabolism and bioactivation, accounting for about 75% of the total number of different metabolic reactions \[[@B10]\]. CYP enzyme names and genetic variants were mapped from the Human Cytochrome P450 (CYP) Allele Nomenclature Database (<http://www.cypalleles.ki.se/>). This site contains the CYP450 genetic mutation effect on the protein sequence and enzyme activity with associated references.

*Transport Proteins* are proteins which serves the function of moving other materials within an organism. Transport proteins are vital to the growth and life of all living things. Transport proteins involved in the movement of ions, small molecules, or macromolecules, such as another protein, across a biological membrane. They are integral membrane proteins; that is they exist within and span the membrane across which they transport substances. Their names and genetic variants were mapped from the Transporter Classification Database (<http://www.tcdb.org>). In addition, we also added the probe substrates and probe inhibitors to each one of the metabolism and transportation enzymes (see prescribed description).

*Drug* names was created using the drug names from DrugBank 3.0 \[[@B11]\]. DrugBank consists of 6,829 drugs which can be grouped into different categories of FDA-approved, FDA approved biotech, nutraceuticals, and experimental drugs. The drug names are mapped to generic names, brand names, and synonyms.

*Subject* included the existing ontologies for human disease ontology (DOID), suggested Ontology for Pharmacogenomics (SOPHARM),, and mammalian phenotype (MP) from <http://bioportal.bioontology.org> (see Table [1](#T1){ref-type="table"})The PK ontology was implemented with Protégé \[[@B12]\] and uploaded to the BioPortal ontology platform.

PK corpus
---------

A PK abstract corpus was constructed to cover four primary classes of PK studies: clinical PK studies (n = 56); clinical pharmacogenetic studies (n = 57); *in vivo* DDI studies (n = 218); and *in vitro* drug interaction studies (n = 210). The PK corpus construction process is a manual process. The abstracts of clinical PK studies were selected from our previous work, in which the most popular CYP3A substrate, midazolam was investigated \[[@B4]\]. The clinical pharmacogenetic abstracts were selected based on the most polymorphic CYP enzyme, CYP2D6. We think these two selection strategies represent very well all the *in vivo* PK and PG studies. In searching for the drug interaction studies, the abstracts were randomly selected from a PubMed query, which used probe substrates/inhibitors/inducers for metabolism enzymes reported in the Table [6](#T6){ref-type="table"}.

Once the abstracts have been identified in four classes, their annotation is a manual process (Figure [1](#F1){ref-type="fig"}). The annotation was firstly carried out by three master level annotators (Shreyas Karnik, Abhinita Subhadarshini, and Xu Han), and one Ph.D. annotator (Lang Li). They have different training backgrounds: computational science, biological science, and pharmacology. Any differentially annotated terms were further checked by Sara K. Quinney and David A. Flockhart, one Pharm D. and one M.D. scientists with extensive pharmacology training background. Among the disagreed annotations between these two annotators, a group review was conducted (Drs Quinney, Flockhart, and Li) to reach the final agreed annotations. In addition a random subset of 20% of the abstracts that had consistent annotations among four annotators (3 masters and one Ph.D.), were double checked by two Ph.D. level scientists.

![PK corpus annotation flow chart.](1471-2105-14-35-1){#F1}

A structured annotation scheme was implemented to annotate three layers of pharmacokinetics information: key terms, DDI sentences, and DDI pairs (Figure [2](#F2){ref-type="fig"}). DDI sentence annotation scheme depends on the key terms; and DDI annotations depend on the key terms and DDI sentences. Their annotation schemes are described as following.

![A three level hierarchical PK and DDI annotation scheme.](1471-2105-14-35-2){#F2}

Key terms include drug names, enzyme names, PK parameters, numbers, mechanisms, and change. The boundaries of these terms among different annotators were judged by the following standard.

• *Drug names* were defined mainly on DrugBank 3.0 \[[@B11]\]. In addition, drug metabolites were also tagged, because they are important in *in vitro* studies. The metabolites were judged by either prefix or suffix: oxi, hydroxyl, methyl, acetyl, N-dealkyl, N-demethyl, nor, dihydroxy, O-dealkyl, and sulfo. These prefixes and suffixes are due to the reactions due to phase I metabolism (oxidation, reduction, hydrolysis), and phase II metabolism (methylation, sulphation, acetylation, glucuronidation) \[[@B13]\].

• *Enzyme names* covered all the CYP450 enzymes. Their names are defined in the human cytochrome P450 allele nomenclature database, <http://www.cypalleles.ki.se/>. The variations of the enzyme or gene names were considered. Its regular expression is (?:cyp\|CYP\|P450\|CYP450)?\[0--9\]\[a-zA-Z\]\[0--9\](?:\\\*\[0--9\])?\$.

• *PK parameters* were annotated based on the defined *in vitro* and *in vivo* PK parameter ontology in Table [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}. In addition, some PK parameters have different names, CL = clearance, t1/2 = half-life, AUC = area under the concentration curve, and AUCR = area under the concentration curve ratio.

• *Numbers* such as dose, sample size, the values of PK parameters, and p-values were all annotated. If presented, their units were also covered in the annotations.

• *Mechanisms* denote the drug metabolism and interaction mechanisms. They were annotated by the following regular expression patterns: inhibit(e(s\|d)?\|ing\|ion(s)?\|or)\$, catalyz(e(s\|d)?\|ing)\$, correlat(e(s\|d)?\|ing\|ion(s)?)\$, metaboli(z(e(s\|d)?\|ing)\|sm)\$, induc(e(s\|d)?\|ing\|tion(s)?\|or)\$, form((s\|ed)?\|ing\|tion(s)?\|or)\$, stimulat(e(s\|d)?\|ing\|ion(s)?)\$, activ(e(s)?\|(at)(e(s\|d)?\|ing\|ion(s)?))\$, and suppress(e(s\|d)?\|ing\|ion(s)?)\$.

• *Change* describes the change of PK parameters. The following words were annotated in the corpus to denote the change: strong(ly)?, moderate(ly)?, high(est)?(er)?, slight(ly)?, strong(ly)?, moderate(ly)?, slight(ly)?, significant(ly)?, obvious(ly)?, marked(ly)?, great(ly)?, pronounced(ly)?, modest(ly)?, probably, may, might, minor, little, negligible, doesn't interact, affect((s\|ed)?\|ing\|ion(s)?)?\$, reduc(e(s\|d)?\|ing\|tion(s)?)\$, and increas(e(s\|d)?\|ing)\$.

The middle level annotation focused on the drug interaction sentences. Because two interaction drugs were not necessary all presented in the sentence, sentences were categorized into two classes:

• Clear DDI Sentence (CDDIS): two drug names (or drug-enzyme pair in the *in vitro* study) are in the sentence with a clear interaction statement, i.e. either interaction, or non-interaction, or ambiguous statement (i.e. such as possible or might and etc.).

• Vague DDI Sentence (VDDIS): One drug or enzyme name is missed in the DDI sentence, but it can be inferred from the context. Clear interaction statement also is required.

Once DDI sentences were labeled, the DDI pairs in the sentences were further annotated. Because the fundamental difference between *in vivo* DDI studies and *in vitro* DDI studies, their DDI relationships were defined differently. In *in vivo* studies, three types of DDI relationships were defined (Table [8](#T8){ref-type="table"}): DDI, ambiguous DDI (ADDI), and non-DDI (NDDI). Four conditions are specified to determine these DDI relationships. Condition 1 (C1) requires that at least one drug or enzyme name has to be contained in the sentence; condition 2 (C2) requires the other interaction drug or enzyme name can be found from the context if it is not from the same sentence; condition 3 (C3) specifies numeric rules to defined the DDI relationships based on the PK parameter changes; and condition 4 (C4) specifies the language expression patterns for DDI relationships. Using the rules summarized in Table [8](#T8){ref-type="table"}, DDI, ADDI, and NDDI can be defined by C1 \^ C2 \^ (C3 \^ C4). The priority rank of *in vivo* PK parameters is AUC \> CL \> t~1/2~ \> C~max~. In *in vitro* studies, six types of DDI relationships were defined (Table [8](#T8){ref-type="table"}). DDI, ADDI, NDDI were similar to *in vivo* DDIs, but three more drug-enzyme relationships were further defined: DEI, ambiguous DEI (ADEI), and non-DDI (NDEI). C1, C2, and C4 remained the same for *in vitro* DDIs. The main difference is in C3, in which either Ki or IC50 (inhibition) or EC50 (induction) were used to defined DDI relationship quantitatively. The priority rank of *in vitro* PK parameters is Ki \> IC50. Table [9](#T9){ref-type="table"} presented eight examples of how DDIs or DEIs were determined in the sentences.

###### 

DDI definitions in corpus

  **DDI relationship**       **C1**                                                                                                                                                     **C2**                                                                             **C3\*\***                                                                                              **C4\*\***
  -------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  **IN VIVO STUDY**                                                                                                                                                                                                                                                                                                                                                                
  **DDI**                    **Yes**                                                                                                                                                    **Yes**                                                                            The PK parameter with the highest priority\* must satisfy p-value \<0.05 and FC \> 1.50 or FC \< 0.67   Significant, obviously, markedly, greatly, pronouncedly and etc.
  **Ambiguous DDI (ADDI)**   The PK parameter with the highest priority\* in the conditions of p-value \<0.05 but 0.67 \< FC \< 1.50; or FC \>1.50 or FC \<0.67, but p-value \> 0.05.   Modestly, moderately, probably, may, might, and etc.                                                                                                                                       
  **Non-DDI (NDDI)**         The PK parameter with the highest priority\*are in the condition of p-value \> 0.05 and 0.67 \< FC \< 1.50                                                 Minor significance, slightly, little or negligible effect, doesn't interact etc.                                                                                                           
  **IN VITRO STUDY**                                                                                                                                                                                                                                                                                                                                                               
  **DDI**                    **Yes**                                                                                                                                                    **Yes**                                                                            (0\< Ki \< 10 or 0\< EC50 \< 10 microM, and p-value \<0.05)                                             Significant, obviously, markedly, greatly, pronouncedly and etc.
  **DEI**                                                                                                                                                                                                                                                                                                                                                                          
  **Ambiguous DDI (ADDI)**   (10 \< Ki \< 100 or 10 \< EC50 \< 100 microM, and p-value \<0.05 or vice versa)                                                                            Modestly, moderately, probably, may, might, and etc.                                                                                                                                       
  **Ambiguous DEI (ADEI)**                                                                                                                                                                                                                                                                                                                                                         
  **Non-DDI (NDDI)**         (Ki \> 100 microM or EC50 \> 100 microM, and p-value \>0.05)                                                                                               Minor significance, slightly, little or negligible effect, doesn't interact etc.                                                                                                           
  **Non-DEI (NDEI)**                                                                                                                                                                                                                                                                                                                                                                

Note:

C1: At least one drug or enzyme name has to be contained in the sentence.

C2: Need to label the drug name if it is not from the same sentence.

C3: PK-parameter and value dependent.

C4: Significance statement.

\*Priority issue: When C3 and C4 occur and conflict, C3 dominates the sentence.\*\*For the priority of PK parameters: AUC \> CL \> t~1/2~ \> C~max;~; the priority of *in vitro* PK parameters: Ki\>IC50.

###### 

Examples of DDI definitions

  **PMID**       **DDI sentence**                                                                                                                                                                                                                                                                                                                                            **Relationship and commend**
  -------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  **20012601**   The pharmacokinetic parameters of *verapamil* were *significantly* altered by the co-administration of *lovastatin* compared to the control.                                                                                                                                                                                                                Because of the words, "significantly", (Verapamil, lovastatin) is a **DDI**.
  **20209646**   The *clearance* of *mitoxantrone* and *etoposide* was *decreased* by *64%* and *60%*, respectively, when combined with *valspodar*.                                                                                                                                                                                                                         Because of the fold changes were less than 0.67, (*mitoxantrone, valspodar*.) and (*etoposide, valspodar*) are **DDIs**.
  **20012601**   The *(AUC (0-infinity))* of *norverapamil* and the terminal *half-life* of *verapamil did not significantly changed* with *lovastatin* coadministration.                                                                                                                                                                                                    Because of the words, "not significantly changed", *(verapamil*, *ovastatin*) is a **NDDI**.
  **17304149**   Compared with placebo, *itraconazole* treatment *significantly increase* the peak plasma concentration (*Cmax*) of paroxetine by 1.3 fold (6.7 2.5 versus 9.0 3.3 ng/mL, P≤0.05) and the area under the plasma concentration-time curve from zero to 48 hours \[*AUC(*0*--*48)\] of *paroxetine* by *1.5 fold* (137 73 versus 199 91 ng\*h/mL, *P≤0.01*).   AUC has a higher rank than Cmax, and it had a 1.5 fold-change and less than 0.05 p-value, thus, (*itraconazole*, *paroxetine)* is a **DDI**.
  **13129991**   The mean (SD) *urinary ratio* of *dextromethorphan* to its metabolite was *0.006* (0.010) at baseline and *0.014* (0.025) after *St John's wort* administration *(P=.26)*                                                                                                                                                                                   The change in PK parameter is more than 1.5 fold but P-value is \>0.05. Thus, (dextromethorphan, St John's wort) is an **ADDI**.
  **19904008**   The obtained results show that *perazine* at its therapeutic concentrations is a *potent inhibitor* of human *CYP1A2.*                                                                                                                                                                                                                                      Because of words, "potent inhibitor", (perazine, CYP1A2) is a **DEI**.
  **19230594**   After human hepatocytes were exposed to 10 microM *YM758*, microsomal activity and mRNA level for *CYP1A2* were *not induced* while those for *CYP3A4* were *slightly induced*.                                                                                                                                                                             Because of words, "not induced" and "slightly induced", (YM758, CYP1A2) and (YM758, CYP1A2) are **NDEIs**.
  **19960413**   From these results, *DPT* was characterized to be a competitive *inhibitor* of *CYP2C9* and *CYP3A4*, with *K(i)* values of *3.5* and *10.8 microM* in HLM and *24.9* and *3.5* microM in baculovirus-insect cell-expressed human CYPs, respectively.                                                                                                       Because K was larger than 10microM, (DPT, CYP2C9) and (DPT, CYP3A4) are **ADEIs**.

Krippendorff's alpha \[[@B14]\] was calculated to evaluate the reliability of annotations from four annotators. The frequencies of key terms, DDI sentences, and DDI pairs are presented in Table [10](#T10){ref-type="table"}. Their Krippendorff's alphas are 0.953, 0.921, and 0.905, respectively. Please note that the total DDI pairs refer to the total pairs of drugs within a DDI sentence from all DDI sentences.

###### 

Annotation performance evaluation

  ----------------- --------------------------- ----------------- --------------------------
  **Key Terms**     **Annotation Categories**   **Frequencies**   **Krippendorff's alpha**
                    Drug                        8633              0.953
                    CYP                         3801              
                    PK Parameter                1508              
                    Number                      3042              
                    Mechanism                   2732              
                    Change                      1828              
                    Total words                 97291             
  DDI sentences     CDDI sentences              1191              0.921
  VDDI sentences    120                                           
  Total sentences   4724                                          
  DDI Pairs         DDI                         1239              0.905
  ADDI              300                                           
  NDDI              294                                           
  DEI               565                                           
  ADEI              95                                            
  NDEI              181                                           
                    Total Drug Pairs            12399              
  ----------------- --------------------------- ----------------- --------------------------

The PK corpus was constructed by the following process. Raw abstracts were downloaded from PubMed in XML format. Then XML files were converted into GENIA corpus format following the gpml.dtd from the GENIA corpus \[[@B15]\]. The sentence detection in this step is accomplished by using the Perl module Lingua::EN::Sentence, which was downloaded from The Comprehensive Perl Archive Network (CPAN, <http://www.cpan.org>). GENIA corpus files were then tagged with the prescribed three levels of PK and DDI annotations. Finally, a cascading style sheet (CSS) was implemented to differentiate colours for the entities in the corpus. This feature allows the users to visualize annotated entities. We would like to acknowledge that a DDI Corpus was recently published as part of a text mining competition DDIExtraction 2011 (<http://labda.inf.uc3m.es/> DDIExtraction2011/dataset.html). Their DDIs were clinical outcome oriented, not PK oriented. They were extracted from DrugBank, not from PubMed abstracts. Our PK corpus complements to their corpus very well.

Utility
=======

Example 1: An annotated tamoxifen pharmacogenetics study
--------------------------------------------------------

This example shows how to annotate a pharmacogenetics studies with the PK ontology. We used a published tamoxifen PG study \[[@B16]\]. The key information from this tamoxifen PG trial was extracted as a summary list. Then the pre-processed information was mapped to the PK ontology (column 2 in Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). This PG study investigates the genetics effects (CYP3A4, CPY3A5, CYP2D6, CYP2C9, CYP2B6) on the tamoxifen pharmacokinetics outcome (tamoxifen metabolites) among breast cancer patients. It was a single arm longitudinal study (n = 298), patients took SOLTAMOX^TM^ 20mg/day, and the drug steady state concentration was sampled (1, 4, 8, 12) months after the tamoxifen treatment. The study population was a mixed Caucasian and African American. In additional file [1](#S1){ref-type="supplementary-material"}: Table S1, the trial summary is well organized by the PK ontology.

Example 2 midazolam/ketoconazole drug interaction study
-------------------------------------------------------

This was a cross-over three-phase drug interaction study \[[@B17]\] (n = 24) between midazolam (MDZ) and ketoconazole (KTZ). Phase I was MDZ alone (IV 0.05 mg/kg and PO 4mg); phase II was MDZ plus KTZ (200mg); and phase III was MDZ plus KTZ (400mg). Genetic variable include CYP3A4 and CYP3A5. The PK outcome is the MDZ AUC ratio before and after KTZ inhibition. Its PK ontology based annotation is shown in Additional file [1](#S1){ref-type="supplementary-material"}: Table S1 column three.

Example 3 *in vitro* Pharmacokinetics Study
-------------------------------------------

This was an *in vitro* study \[[@B18]\], which investigated the drug metabolism activities for 3 enzymes, such as CYP3A4, CYP3A5, and CYP3A7 in a recombinant system. Using 10 CYP3A substrates, they compared the relative contribution of 3 enzymes among 10 drug's metabolism. Its PK ontology based annotation is shown in Additional file [1](#S1){ref-type="supplementary-material"}: Table S2.

Example 4 A drug interaction text mining example
------------------------------------------------

We implemented the approach described by \[[@B19]\] for the DDI extraction. Prior to performing DDI extraction, the testing and validation DDI abstracts in our corpus was pre-processed and converted into the unified XML format \[[@B19]\]. The following steps were conducted:

• Drugs were tagged in each of the sentences using dictionary based on DrugBank. This step revised our prescribed drug name annotations in the corpus. One purpose is to reduce the redundant synonymous drug names. The other purpose is only keep the parent drugs and remove the drug metabolites from the tagged drug names from our initial corpus, because parent drugs and their metabolites rarely interacts. In addition, enzymes (i.e. CYPs) were also tagged as drugs, since enzyme-drug interactions have been extensively studied and published. The regular expression of enzyme names in our corpus was used to remove the redundant synonymous gene names.

• Each of the sentences was subjected to tokenization, PoS tags and dependency tree generation using the Stanford parser \[[@B20]\].

• C~2~^*n*^drug pairs form the tagged drugs in a sentence were generated automatically, and they were assigned with default labels as no-drug interaction. Please note that if a sentence had only one drug name, this sentence didn't have a DDI. This setup limited us considering only CDDI sentence in our corpus.

• The drug interaction labels were then manually flipped based on their true drug interaction annotations from the corpus. Please note that our corpus had annotated DDIs, ADDIs, NDDIs, DEIs, ADEIs, and NDEIs. Here only DDIs and DEIs were labeled as true DDIs. The other ADDIs, NDDIs, DEIs, and ADEIs were all categorized into the no-drug interactions.

Then sentences were represented with dependency graphs using interacting components (drugs) (Figure [3](#F3){ref-type="fig"}). The graph representation of the sentence was composed of two items: i) One dependency graph structure of the sentence; ii) a sequence of PoS tags (which was transformed to a linear order "graph" by connecting the tags with a constant edge weight). We used the Stanford parser \[[@B20]\] to generate the dependency graphs. Airola et al. proposed to combine these two graphs to one weighted, directed graph. This graph was fed into a support vector machine (SVM) for DDI/non-DDI classification. More details about the all paths graph kernel algorithm can be found in \[[@B19]\]. A graphical representation of the approach is presented in Figure [3](#F3){ref-type="fig"}.

![Drug interaction extraction algorithm flow chart.](1471-2105-14-35-3){#F3}

DDI extraction was implemented in the *in vitro* and *in vivo* DDI corpus separately. Table [11](#T11){ref-type="table"} presented the training sample size and testing sample size in both corpus sets. Then Table [12](#T12){ref-type="table"} presents the DDI extraction performance. In extracting *in vivo* DDI pairs, the precision, recall, and F-measure in the testing set are 0.67, 0.79, and 0.73, respectively. In the *in vitro* DDI extraction analysis, the precision, recall, and F-measure are 0.47, 0.58, 0.52 respectively in the *in vitro* testing set. In our early DDI research published in the DDIExtract 2011 Challenge \[[@B21]\], we used the same algorithm to extract both *in vitro* and *in vivo* DDIs at the same time, the reported F-measure was 0.66. This number is in the middle of our current *in vivo* DDI extraction F-measure 0.73 and *in vitro* DDI extraction F-measure 0.52.

###### 

DDI data description

  **Datasets**              **Abstracts**   **Sentences**   **DDI pairs**   **True DDI pairs**
  ------------------------- --------------- --------------- --------------- --------------------
  *in vivo* DDI training    174             2112            2024            359
  *in vivo* DDI testing     44              545             574             45
  *in vitro* DDI training   168             1894            7122            783
  in vitro DDI testing      42              475             1542            146

###### 

DDI extraction performance

  **Datasets**             **precision**   **recall**   **f-measure**
  ------------------------ --------------- ------------ ---------------
  *in vivo* DDI Training   0.67            0.78         0.72
  *in vivo* DDI Testing    0.67            0.79         0.73
  in vitro DDI Training    0.51            0.59         0.55
  in vitro DDI Testing     0.47            0.58         0.52

Error analysis was performed in testing samples. Table [13](#T13){ref-type="table"} summarized the results. Among the known reasons for the false positives and false negatives, the most frequent one is that there are multiple drugs in the sentence, or the sentence is long. The other reasons include that there is no direct DDI relationship between two drugs, but the presence of some words, such as dose, increase, and etc., may lead to a false positive prediction; or DDI is presented in an indirect way; or some NDDI are inferred due to some adjectives (little, minor, negligible).

###### 

DDI extraction error analysis from testing DDI sets

  **No.**   **Error categories**                                                                                                                                              **Error type**   **Frequency**                                                                                                                                                                                                                                                                                                     **examples**   
  --------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1         There are multiple drugs in the sentence, and the sentence is long.                                                                                               FP               6                                                                                                                                                                                                                                                                                                                 34             PMID: 12426514. In 3 subjects with measurable concentrations in the single-dose study, rifampin significantly decreased the mean maximum plasma concentration (C(max)) and area under the plasma concentration-time curve from 0 to 24 h \[AUC(0--24)\] of praziquantel by 81% (P \<.05) and 85% (P \<.01), respectively, whereas rifampin significantly decreased the mean C(max) and AUC(0--24) of praziquantel by 74% (P \<.05) and 80% (P \<.01), respectively, in 5 subjects with measurable concentrations in the multiple-dose study
  FN        2                                                                                                                                                                 17               PMID: 10608481. Erythromycin and ketoconazole showed a clear inhibitory effect on the 3-hydroxylation of lidocaine at 5 microM of lidocaine (IC50 9.9 microM and 13.9 microM, respectively), but did not show a consistent effect at 800 microM of lidocaine (IC50 \>250 microM and 75.0 microM, respectively).                  
  2         There is no direct DDI relationship between two drugs, but the presence of some words, such as dose, increase, and etc. may lead to a false positive prediction   FP               6                                                                                                                                                                                                                                                                                                                 14             PMID: 17192504. A significant fraction of patients to be treated with HMR1766 is expected to be maintained on warfarin
  3         DDI is presented in an indirect way.                                                                                                                              FN               2                                                                                                                                                                                                                                                                                                                 19             PMID: 11994058. In CYP2D6 poor metabolizers, systemic exposure was greater after chlorpheniramine alone than in extensive metabolizers, and administration of quinidine resulted in a slight increase in CLoral.
  4         Design issue. Some NDDI are inferred due to some adjectives (little, minor, negligible)                                                                           FP               1                                                                                                                                                                                                                                                                                                                 3              PMID: 10223772. In contrast,the effect of ranitidine or ebrotidine on CYP3A activity *in vivo* seems to have little clinical significance.
  5         Unknown                                                                                                                                                           FP               5                                                                                                                                                                                                                                                                                                                 44             PMID: 10383922. CYP1A2, CYP2A6, and CYP2E1 activities were not significantly inhibited by azelastine and the two metabolites.
                                                                                                                                                                              FN               6                                                                                                                                                                                                                                                                                                                 26             PMID: 10681383. However, the most unusual result was the interaction between testosterone and nifedipine.

Conclusions and discussions
===========================

A comprehensive PK ontology was constructed. It annotates both *in vitro* PK experiments and *in vivo* PK studies. Using our PK ontology, a PK corpus was also developed. It consists of four classes of PK studies: *in vivo* PK studies, *in vivo* PG studies, *in vivo* DDI interaction studies, and *in vitro* DDI studies. This PK corpus is a highly valuable resource for text mining drug interactions relationship.

We previously had developed entity recognition algorithm or tools to tag PK parameters and their associated numerical data \[[@B4]\]. We had shown that for one drug, midazolam, we have achieved very high accuracy and recall rate in tagging PK parameter, clearance (CL), and its associated numerical values. However, using our newly developed PK corpus, we cannot regain such a good performance in a more general class of drugs and PK parameters. This area will need much further investigation.

We would like to acknowledge that a DDI Corpus was recently published as part of a text mining competition DDIExtraction 2011 (<http://labda.inf.uc3m.es/DDIExtraction2011/dataset.html>). Their DDIs were clinical outcome oriented, not PK oriented. They were extracted from DrugBank, not from PubMed abstracts. Our PK corpus complements to their corpus very well.

Availability and requirements
=============================

PK ontology is available in OWL for download at <http://rweb.compbio.iupui.edu/corpus/ontology/>, which can be accessed by using any OWL editor/viewer, e.g., protégé. PK corpuses are available in XML at <http://rweb.compbio.iupui.edu/corpus/>.

Abbreviation
============

ADMET: Absorption, disposition, metabolism, excretion, and transportation; DDI: Drug-drug interaction; KTZ: Ketoconazole; MDZ: Midazolam; POS: Part of speech; PK: Pharmacokinetics; PG: Pharmacogenetics.
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